SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+16.97%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$1.2B
AUM Growth
+$1.2B
(+6%)
Cap. Flow
-$60.2M
Cap. Flow
% of AUM
-5%
Top 10 Holdings %
Top 10 Hldgs %
37.95%
Holding
109
New
16
Increased
24
Reduced
36
Closed
22
Top Buys
| 1 |
Grifois
GRFS
|
$40.2M |
| 2 |
Sanofi
SNY
|
$31.7M |
| 3 |
QuidelOrtho
QDEL
|
$31.3M |
| 4 |
Eli Lilly
LLY
|
$17.1M |
| 5 |
Krystal Biotech
KRYS
|
$16.6M |
Top Sells
| 1 |
TG Therapeutics
TGTX
|
$26M |
| 2 |
Nurix Therapeutics
NRIX
|
$22.2M |
| 3 |
Penumbra
PEN
|
$22.2M |
| 4 |
Vaxcyte
PCVX
|
$18.1M |
| 5 |
Humana
HUM
|
$16.6M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Neuropace
NPCE
$303M
| $17M | 1.31% |
2,433,168
| – | – |
|
27
Evolus
EOLS
$494M
| $16.8M | 1.3% |
1,037,680
-114,320
| -10% | -$1.85M |
|
28
Alnylam Pharmaceuticals
ALNY
$58.5B
| $16.3M | 1.27% |
59,400
-12,300
| -17% | -$3.38M |
|
29
ANI Pharmaceuticals
ANIP
$2.03B
| $16M | 1.24% |
+269,000
| New | +$16M |
|
30
Elevance Health
ELV
$71.8B
| $15.4M | 1.19% |
+29,650
| New | +$15.4M |
|
31
Rigel Pharmaceuticals
RIGL
$697M
| $15.1M | 1.17% |
934,788
-108,909
| -10% | -$1.76M |
|
32
Praxis Precision Medicines
PRAX
$958M
| $14.9M | 1.16% |
259,398
-273,617
| -51% | -$15.7M |
|
33
Keros Therapeutics
KROS
$618M
| $13M | 1.01% |
224,600
+3,000
| +1% | +$174K |
|
34
CG Oncology
CGON
$2.04B
| $12.9M | 1% |
340,585
-84,000
| -20% | -$3.17M |
|
35
Immunic
IMUX
$80.9M
| $12M | 0.93% |
7,293,007
| – | – |
|
36
Bausch Health
BHC
$2.74B
| $11.6M | 0.9% |
1,424,000
+218,000
| +18% | +$1.78M |
|
37
Pharvaris
PHVS
$1.39B
| $11.1M | 0.86% |
598,169
+198,739
| +50% | +$3.68M |
|
|
LBPH
38
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $10.6M | 0.82% |
+318,269
| New | +$10.6M |
|
39
Orthofix Medical
OFIX
$592M
| $9.48M | 0.73% |
606,933
+555,933
| +1,090% | +$8.68M |
|
40
Verastem
VSTM
$569M
| $8.46M | 0.65% |
2,827,963
+1,166,666
| +70% | +$3.49M |
|
41
Enanta Pharmaceuticals
ENTA
$180M
| $8.14M | 0.63% |
785,546
-14,000
| -2% | -$145K |
|
42
OrthoPediatrics
KIDS
$536M
| $7.83M | 0.61% |
288,945
-20,555
| -7% | -$557K |
|
43
Arcellx
ACLX
$3.85B
| $7.77M | 0.6% |
93,031
-77,710
| -46% | -$6.49M |
|
44
Nuvalent
NUVL
$5.52B
| $7.61M | 0.59% |
74,357
-97,431
| -57% | -$9.97M |
|
45
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $7.56M | 0.59% |
302,500
+102,500
| +51% | +$2.56M |
|
46
Biodesix
BDSX
$62.6M
| $7.19M | 0.56% |
4,038,065
-2,073,899
| -34% | -$3.69M |
|
47
Takeda Pharmaceutical
TAK
$47.3B
| $7.11M | 0.55% |
+500,000
| New | +$7.11M |
|
48
Relay Therapeutics
RLAY
$619M
| $6.44M | 0.5% |
+910,000
| New | +$6.44M |
|
49
Summit Therapeutics
SMMT
$17.6B
| $6.24M | 0.48% |
+285,000
| New | +$6.24M |
|
50
Enliven Therapeutics
ELVN
$1.2B
| $6.12M | 0.47% |
239,705
-529,558
| -69% | -$13.5M |
|